A Phase 2 interventional study of RFB002 and Laser photocoagulation in Diabetic Macular Edema and Visual Impairment, sponsored by Novartis Pharmaceuticals. Completed at 17 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-03.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing ranibizumab in Vision Disorders — none open to participants now, none under way, none of them phase 3. Ranibizumab · Vision Disorders.
Among the 26 studies testing ranibizumab in Vision Disorders, this one is the 21st largest by enrollment, is the only one that started in 2009, is one of 3 in phase 2, and was the 4th registered.
361 studies on the registry are indexed under Vision Disorders; 85 are open to participants now.
Browse Vision Disorders studies →None of the 26 studies testing ranibizumab in Vision Disorders is open now. The open studies under Vision Disorders, anywhere →
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 46 Vision Disorders studies recruiting now, 21 (46%) set no upper age limit and 16 (35%) stop at 75 or younger; 18 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 83 is above the median of 75 across 245 interventional studies indexed under Vision Disorders.
Median enrollment 178 across the 26 interventional studies. Of the 22 that completed or were terminated, 19 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 26 have an industry lead sponsor. The 6 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,721 studies on the registry; 222 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
32 studies in Vision Disorders by Novartis: none open now, none under way, none of them phase 3. Of 30 finished, 25 (83%) have results posted.
Among the 32 studies in Vision Disorders by Novartis, this one is the 26th largest by enrollment of the 31 interventional ones that give a count, is the only one that started in 2009, is one of 3 in phase 2, and was the 1st registered.
Novartis’s Vision Disorders studies by the year they started, since 2009.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing ranibizumab in Vision Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 32 in Vision Disorders:
This tab as a report to print or save as PDF → With an account.
This study will assess the efficacy and safety of ranibizumab (intravitreal injections) versus laser treatment in patients with visual impairment due to diabetic macular edema.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
In the study eye:
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RFB002 0.5 mg was administered to the study eye with a single monthly intravitreal injection on day 1, day 30 and day 60. After day 90, if stable vision was not achieved, a monthly injection of RFB002 0.5 mg was administered until stable vision was achieved.
Drug: RFB002
At least one treatment of laser photocoagulation was applied on day 1. The maximum number of laser photocoagulation treatments was 4.
Procedure: Laser photocoagulation
0.5 mg
Also known as: Ranibizumab
Mean Change From Baseline in Best Corrected Visual Acuity (BCVA)
Visual acuity (VA) was assessed on the study eye during every study visit using best correction determined from protocol refraction. VA measurements were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters.
Time frame: Baseline, 12 months
Percentage of Participants With Improvement in BCVA
Visual acuity (VA) was assessed on the study eye during every study visit using best correction determined from protocol refraction. VA measurements were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters.
Time frame: 12 months
Evolution of Mean Change From Baseline in BCVA by Study Visit
Visual acuity (VA) was assessed on the study eye during every study visit using best correction determined from protocol refraction. VA measurements were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters.
Time frame: Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
Percentage of Participants With VA > 73 Letters With Ranibizumab (0.5 mg) vs Laser.
VA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters.
Time frame: 12 months
Mean Change From Baseline in Central Retinal Thickness (CRT) by Study Visit
CRT was assessed by Optical Coherence Tomography (OCT).
Time frame: Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
Percentage of CRT Change From Baseline by Study Visit
CRT was assessed by Optical Coherence Tomography (OCT).
Time frame: Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
| Milestone | RFB002 | Laser Photocoagulation |
|---|---|---|
| Started | 40 | 43 |
| Safety set | 39 | 43 |
| Intent to treat | 35 | 38 |
| Completed | 31 | 32 |
| Not completed | 9 | 11 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Abnormal laboratory values | 0 | 1 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Adverse event | 2 | 4 |
| Withdrew: Administration problems | 0 | 1 |
| Withdrew: Protocol deviations | 5 | 4 |
Visual acuity (VA) was assessed on the study eye during every study visit using best correction determined from protocol refraction. VA measurements were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters.
| letters | RFB002 | Laser Photocoagulation |
|---|---|---|
| Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) | 9.41 ± 9.15 | 5.79 ± 9.40 |
Visual acuity (VA) was assessed on the study eye during every study visit using best correction determined from protocol refraction. VA measurements were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters.
| Percentage of participants | RFB002 | Laser Photocoagulation |
|---|---|---|
| Percentage of Participants With Improvement in BCVA | 74.29 | 68.42 |
Visual acuity (VA) was assessed on the study eye during every study visit using best correction determined from protocol refraction. VA measurements were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters.
| letters | RFB002 | Laser Photocoagulation |
|---|---|---|
| Month 1 (n=34,38) | 4.56 ± 7.38 | 1.32 ± 7.99 |
| Month 2 (n=31,38) | 4.61 ± 6.55 | 1.89 ± 8.04 |
| Month 3 (n=33,38) | 6.24 ± 6.41 | 3.11 ± 7.83 |
| Month 4 (n=33,37) | 6.33 ± 7.40 | 2.76 ± 8.66 |
| Month 5 (n=31,37) | 7.03 ± 8.00 | 3.38 ± 8.95 |
| Month 6 (n=33,35) | 7.61 ± 6.88 | 4.11 ± 7.65 |
| Month 7 (n=33,33) | 7.91 ± 7.16 | 3.85 ± 7.97 |
| Month 8 (n=32,34) | 8.00 ± 7.77 | 3.21 ± 7.75 |
| Month 9 (n=32,33) | 8.44 ± 8.78 | 6.00 ± 9.81 |
| Month 10 (n=31,32) | 7.32 ± 8.17 | 5.84 ± 9.14 |
| Month 11 (n=32,32) | 7.69 ± 8.88 | 6.44 ± 8.32 |
| Month 12 (n=32,33) | 9.41 ± 9.15 | 5.79 ± 9.40 |
VA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters.
| Percentage of participants | RFB002 | Laser Photocoagulation |
|---|---|---|
| Percentage of Participants With VA > 73 Letters With Ranibizumab (0.5 mg) vs Laser. | 54.29 | 23.68 |
CRT was assessed by Optical Coherence Tomography (OCT).
| micrometers | RFB002 | Laser Photocoagulation |
|---|---|---|
| Month 1 (n=33,37) | -50.18 ± 62.23 | -21.86 ± 82.86 |
| Month 2 (n=31,38) | -69.52 ± 65.10 | -14.21 ± 66.95 |
| Month 3 (n=33,37) | -80.64 ± 87.06 | -43.16 ± 89.74 |
| Month 4 (n=33,38) | -81.79 ± 92.14 | -37.66 ± 83.29 |
| Month 5 (n=30,37) | -77.77 ± 73.47 | -28.92 ± 91.51 |
| Month 6 (n=33,34) | -93.73 ± 79.42 | -40.47 ± 100.12 |
| Month 7 (n=33,35) | -92.76 ± 79.55 | -60.94 ± 110.05 |
| Month 8 (n=32,34) | -92.41 ± 82.27 | -64.82 ± 110.05 |
| Month 9 (n=32,34) | -81.59 ± 81.38 | -74.59 ± 112.75 |
| Month 10 (n=31,31) | -83.32 ± 81.56 | -84.39 ± 102.79 |
| Month 11 (n=32,33) | -98.03 ± 76.75 | -94.85 ± 114.67 |
| Month 12 (n=32,33) | -76.28 ± 76.56 | -86.00 ± 115.53 |
CRT was assessed by Optical Coherence Tomography (OCT).
| Percentage change | RFB002 | Laser Photocoagulation |
|---|---|---|
| Month 1 (n=33,37) | -12.06 ± 15.16 | -3.01 ± 17.52 |
| Month 2 (n=31,38) | -15.61 ± 13.90 | -2.20 ± 15.24 |
| Month 3 (n=33,37) | -18.25 ± 17.09 | -7.97 ± 17.80 |
| Month 4 (n=33,38) | -18.00 ± 17.93 | -6.99 ± 17.18 |
| Month 5 (n=30,37) | -18.21 ± 15.68 | -6.39 ± 19.27 |
| Month 6 (n=33,34) | -20.69 ± 15.85 | -8.55 ± 21.06 |
| Month 7 (n=33,35) | -21.11 ± 15.68 | -12.50 ± 23.05 |
| Month 8 (n=32,34) | -21.20 ± 16.43 | -13.02 ± 20.95 |
| Month 9 (n=32,34) | -19.17 ± 17.95 | -15.68 ± 21.87 |
| Month 10 (n=31,31) | -19.55 ± 17.34 | -17.24 ± 19.63 |
| Month 11 (n=32,33) | -22.65 ± 15.85 | -19.04 ± 22.31 |
| Month 12 (n=32,33) | -18.23 ± 16.66 | -16.59 ± 25.06 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| RFB002 | — | 3/39 (7.7%) | 2/39 (5.1%) |
| Laser Photocoagulation | — | 2/43 (4.7%) | 3/43 (7%) |
| Event | RFB002 | Laser Photocoagulation |
|---|---|---|
| Cardiac failure acuteCardiac disorders | 1/39 | 0/43 |
| Cerebral infarctionNervous system disorders | 1/39 | 0/43 |
| Necrosis ischaemicVascular disorders | 1/39 | 0/43 |
| Cardiac failure congestiveCardiac disorders | 0/39 | 1/43 |
| Penile cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/39 | 1/43 |
| Event | RFB002 | Laser Photocoagulation |
|---|---|---|
| Cataract operationSurgical and medical procedures | 0/39 | 3/43 |
| PharyngitisInfections and infestations | 2/39 | 0/43 |
| Age, Continuous(Years) | RFB002 | Laser Photocoagulation | Total |
|---|---|---|---|
| Mean | 61.31 ± 8.94 | 65.47 ± 9.40 | 63.49 ± 9.36 |
| Sex: Female, Male(Participants) | RFB002 | Laser Photocoagulation | Total |
|---|---|---|---|
| Female | 15 | 18 | 33 |
| Male | 24 | 25 | 49 |
The record gives a start of Nov 2009, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2014, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab